...Juan Chen; Zhigao Xiang; Zhuo Zhang; Yan Yang; Kai Shu; Ting Lei Introduction: Acromegaly patients, in addition to the most prominent physical and endocrine changes, also exhibit a higher risk of cognitive dysfunction. However, the reasons and mechanisms underlying cognitive impairments...

...Paulina Kober; Julia Rymuza; Szymon Baluszek; Maria Maksymowicz; Aleksandra Nyc; Beata J. Mossakowska; Grzegorz Zieliński; Jacek Kunicki; Mateusz Bujko Introduction: Growth hormone secretion by sporadic somatotroph neuroendocrine pituitary tumors (PitNETs) is a major cause of acromegaly...

...Fabio Bioletto; Marco Barale; Nunzia Prencipe; Alessandro Maria Berton; Mirko Parasiliti-Caprino; Valentina Gasco; Ezio Ghigo; Massimo Procopio; Silvia Grottoli Background: Acromegaly is characterized by impaired bone quality and increased fracture risk. However, due to the pathophysiology...

...Yi Yuen Wang; Mueez Waqar; Ahmed Abou-Zeid; Tara Kearney; Carmela Caputo; Julian Davis; Peter Trainer; Claire Higham; Federico Roncaroli; Kanna K. Gnanalingham Introduction: Surgical remission for acromegaly is dependent on a number of factors including tumour size, invasiveness, and surgical...

...: Acromegaly is commonly complicated by arthropathy and skeletal fragility with high risk of vertebral fractures (VFs). Objective: This study aimed to assess whether VFs may be associated with sagittal spine deformities, arthropathy, impaired quality of life (QoL), pain, and disability. Methods: Thirty-eight...

...Leticia P. Leonart; Bruno S. Riveros; Murray D. Krahn; Roberto Pontarolo Objectives: To conduct a cost-utility analysis comparing drug strategies involving octreotide, lanreotide, pasireotide, and pegvisomant for the treatment of patients with acromegaly who have failed surgery, from a Brazilian...

... domains and determines their future life. Understanding that this may occur is important, and health care providers should offer information to prepare the patient for this difficult journey, especially in the case of acromegaly, Cushing disease, or hypopituitarism. In order to maintain a good quality...

...Jau-Ching Wu; Wen-Cheng Huang; Hsuan-Kan Chang; Chin-Chu Ko; Jiing-Feng Lirng; Yu-Chun Chen Background: Acromegaly is so rare that its natural history, including incidence, risk of cancers, and mortality rates, remains elusive. This natural study utilized a nationwide database to provide a better...

... associated with endocrinal disorders using a deep-learning approach to facilitate the process of diagnosis and follow-up. Methods: We collected facial images of patients with hypercortisolism and acromegaly, and we augmented these images with additional negative samples from public databases. A model...

... investigators of the study Background: Long-term remission of acromegaly after somatostatin analog withdrawal has been reported in 18-42% of patients in studies with a relatively small number of patients using different inclusion and remission criteria. The objectives of this study were to establish...

... severity in acromegaly patients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating severe acromegaly. Response to PEGV treatment seems to be influenced by d3-GHR and appears to be more responsive to PEGV, although available results remain conflicting. Objective: To assess the influence...

...Christina Dimopoulou; Sarah M. Leistner; Marcus Ising; Harald J. Schneider; Jochen Schopohl; Sandra Rutz; Robert Kosilek; Richard Frohner; Gunter K. Stalla; Caroline Sievers Objective: Diagnosis of acromegaly is delayed up to 10 years after disease onset despite obvious external/objective changes...

... design, (2) the relative small sample size and (3) the peculiar patient group in which the study has been conducted (all treated with combination medical therapy during their clinical history). However, this can be expected due to the rarity of acromegaly as well as the fact that only a subset...

...Michael Buchfelder; Sven-Martin Schlaffer Since the establishment of transsphenoidal microsurgery as the operative treatment of choice in most patients with acromegaly 40 years ago, a few novel technical developments have evolved. Their application, utility and efficacy will be briefly discussed...

...Andrew S. Powlson; Mark Gurnell Treatment goals in acromegaly include symptom relief, tumour control and reversal of the excess morbidity and mortality associated with the disorder. Cardiovascular complications include concentric biventricular hypertrophy and cardiomyopathy, hypertension, valvular...

...Mark J. Hannon; Ariel L. Barkan; William M. Drake Radiotherapy has, historically, played a central role in the management of acromegaly, and the last 30 years have seen substantial improvements in the technology used in the delivery of radiation therapy. More recently, the introduction of highly...

...Jakob Dal; Edward O. List; Jens Otto L. Jørgensen; Darlene E. Berryman Patients with active acromegaly are frequently insulin resistant, glucose intolerant, and at risk for developing overt type 2 diabetes. At the same time, these patients have a relatively lean phenotype associated...

...Sebastian J.C.M.M. Neggers; Ammar Muhammad; Aart Jan van der Lely Historically, medical treatment of acromegaly has mainly been used as an adjuvant therapy after surgery. In the last decades, an increased range of medical therapy options has been available. Somatostatin analogues have become...

...Susan L. Samson Background: Acromegaly is an insidious neuroendocrine disorder caused by hypersecretion of growth hormone (GH) by a somatotroph adenoma. Somatostatin receptor ligands (SRLs) are recommended as first-line medical therapy in patients for whom surgery has failed or is contraindicated...

...Philippe Chanson Treatment of acromegaly aims to correct (or prevent) tumor compression of surrounding tissues by excising the disease-causing lesion and reduce growth hormone (GH) and IGF-1 levels to normal values. When surgery (the usual first-line treatment) fails to correct GH/IGF-1...